Introduction {#S1}
============

Erythropoietin (EPO) is a small glycoprotein hormone which mostly promotes erythropoiesis, but has also non-haematopoietic, growth-promoting and apoptosis-inhibiting roles ([@R42]; [@R10]; [@R59]). Recently, it has been shown in a mouse model that angiogenesis in tumours is modulated by inducing EPO production via platelet-derived growth factor BB (PDGF-BB) in tumour stromal cells ([@R61]). This system is based on a complex paracrine mechanism involving tumour cells, stromal cells and, in particular, tumour blood vessels. In addition, high amounts of circulating EPO have been shown to stimulate proliferation, migration and cell sprouting of endothelial cells ([@R61]).

In adults, EPO is mainly produced in the kidneys. It binds to the erythropoietin receptor (EPO-R) and activates JAK-STAT-signalling ([@R42]). EPO-R is expressed predominately on erythrocyte progenitors and EPO can be used therapeutically in humans and animals to treat anaemia ([@R21]). Human cancer patients with myelodysplastic disorders are frequently treated with EPO but there is an ongoing discussion about the effect of EPO on tumour cells. Positive effects of EPO for humans ([@R38]; [@R11]; [@R13]; [@R40]; [@R58]; [@R28]) and animals ([@R34]) have been reported. However, several clinical studies showed worse survival times and shorter disease-free intervals after EPO treatment in cancer patients ([@R26], [@R27]; [@R37]; [@R48]; [@R6]).

The presence of EPO and EPO-R has been demonstrated in various tumours in humans and animals ([@R1]; [@R3]; [@R5]; [@R49]; [@R30]; [@R47]; [@R46]) and EPO has been shown to promote angiogenesis, vessel maturity, drug resistance, proliferation and tumour progression ([@R41]; [@R4]). Others have questioned the functionality of EPO-R on tumour cells ([@R51]) due to its low level of expression ([@R54]). In addition, treatment of EPO-R-expressing cell lines with EPO did not enhance cell proliferation in vitro ([@R60]; [@R22]).

Osteosarcoma is considered to be the most frequent bone tumour in dogs and cats ([@R44]) but the metastatic behaviour differs between the two species, with frequent distant metastases in dogs ([@R52]) and a remarkably low metastatic rate in cats ([@R16]). To our knowledge, no studies about EPO and its receptor in bone tumours of cats or dogs have been reported. Recently, PDGFs and PDGF receptors (PDGF-R) were found to be overexpressed in canine osteosarcoma ([@R61]; [@R39]). Moreover, PDGFs and PDGF-Rs were co-expressed, suggesting that an autocrine and/or paracrine loop could be involved ([@R61]; [@R39]). No data about PDGFs exist in feline osteosarcomas.

We hypothesised that the expression pattern of EPO, EPO-R and PDGF-BB in canine and feline osteosarcoma cells differs between the two species and that this may influence tumour growth, angiogenesis and the different metastatic behaviour in the two species.

Materials and methods {#S2}
=====================

Sample collection {#S3}
-----------------

Tumour samples from dogs (*n* = 13) and cats (*n* = 5) were collected after therapeutic limb amputation or euthanasia. Control samples (kidney, bone marrow, cerebellum) were obtained from animals euthanased for reasons other than osteosarcoma. Material was collected from surgery (with informed owner's consent) or from cadaveric clinical waste and was conveyed to the Institute of Pathology of the University of Veterinary Medicine. The study was approved by the Ethical and Animal Welfare Committee of the University of Veterinary Medicine (15 December 2014) and conducted in accordance with the requirements of the Austrian Act on Animal Experiments.

Aliquots of samples were either fixed in 4% buffered formaldehyde or flash frozen in liquid nitrogen with or without RNA later solution (Life Technologies).

Immunohistochemistry {#S4}
--------------------

For immunohistochemistry (IHC), paraffin sections were used and stained with either an anti-EPO, (sc-7956, polyclonal, dilution 1:50; Santa Cruz Biotechnology), an anti-EPO-R (C-20, sc-696, polyclonal, dilution 1:50; Santa Cruz Biotechnology), an anti-EPO-R (M-20 sc-697, polyclonal, dilution 1:75; Santa Cruz Biotechnology) or an anti-PDGF-BB antibody (ab21234, polyclonal, dilution 1:500; Abcam). The evaluation score suggested by [@R14] was used. Specificity of the assays was tested by immunoblotting (see [Appendix: Supplementary material](#SD1){ref-type="supplementary-material"}).

Cell culture {#S5}
------------

Commercially available canine osteosarcoma cells D-17 (LGC Standards) or primary tumour-derived neoplastic cells (canine: COS_1186w and COS_1189; feline: FOS_1077 and FOS_1140; Lonza) were used. Cells were grown in Dulbecco's modified eagle's medium (DMEM) low glucose with 10% foetal calf serum (FCS, Sigma-Aldrich) and 625 pg Amphotericin B (Bio&Sell), 2 nM glutamine (Biochrom) and 1% Pen/Strep/Fungi Mix (Bio&Sell).

AlamarBlue test {#S6}
---------------

Cells were exposed to different concentrations of EPO and proliferation was determined with the alamarBlue test (Resazurin, Sigma Aldrich) to evaluate the functionality of EPO-R as suggested previously ([@R36]; [@R33]; [@R35]). Briefly, 2000 cells/well were seeded in flat bottomed 96-well plates (Sarstedt) and supplemented with 0, 0.001, 0.01, 0.1, 1 or 10 U/mL of alpha erythropoietin (Epoietin, Binocrit 1000 IU/0.5 mL, Sandoz) in 5 μL PBS, or 5 μL PBS alone (control) with or without 10% FCS in the medium. Cells were incubated with EPO for 48 h before 10% alamarBlue was added, and the 570--600 nm ratio was measured on a plate reader (Sunrise, Tecan).

Ki67 immunocytochemistry {#S7}
------------------------

For Ki67 immunocytochemical staining, 23,000 (for D-17, FOS_1077 and FOS_1140) or 46,000 cells (for COS_1189 and COS_1186w) were seeded onto round glass cover slides, and supplemented with 0.001, 1 or 10 U/mL alpha erythropoietin (Epoietin, Binocrit, Sandoz) in 5 μL PBS or PBS alone with or without 10% FCS in the medium. After 48 h, cells were fixed in 4% formaldehyde and stained using an anti-Ki67 antibody (clone 7B11, Life Technologies). For the analysis of Ki67 staining, approximately 1000 cells/slide were counted and classified as stained or unstained to generate a percentage of positive cells.

PCR {#S8}
---

About 30 mg of fresh frozen or RNAlater (Life Technologies)-preserved tissue or pellets of 10^5^--10^6^ cultured cells were used for RNA isolation using either the miRNeasy Mini Kit (Qiagen) or the RNeasy Fibrous Tissue Mini Kit (Qiagen). Concentration and the RNA Integrity Number (RIN) were determined with a 2100 Bioanalyzer (Agilent Technologies) (see [Appendix: Supplementary material](#SD1){ref-type="supplementary-material"}). Using the High-Capacity cDNA Reverse Transcription Kit (Life Technologies), 500 ng RNA/sample was transcribed into cDNA. Feline and canine *EPO* and *PDGF-B* mRNA were detected by qualitative dye-based PCR. Qualitative assessment was performed by melting curve analysis. Canine *EPO* mRNA was measured with a qualitative hydrolysis-probe PCR assay. Quantification of *EPO-R* mRNA was performed by a conventional hydrolysis probe-based format. To compensate for technical variance, data were normalised with the reference genes *OAZ1* ([@R12]; [@R32]) and the canine and feline orthologues of human *C12orf43* ([@R55]).

Statistical evaluation {#S9}
----------------------

RT-qPCR data were analysed using REST 2009 (Qiagen). For the Ki67 and alamarBlue assays, significance was assessed by a linear regression model. A detailed description of the statistical methods is provided in the [Appendix: Supplementary material](#SD1){ref-type="supplementary-material"}.

Results {#S10}
=======

Immunohistochemistry {#S11}
--------------------

Total scores for EPO IHC ranged from 2 to 9 in feline tumours and from 3 to 9 in canine tumours. EPO immunostaining resulted either in a homogenous or heterogeneous pattern within the tumour area. Cytoplasmic and nuclear staining was present ([Figs. 1a, b](#F1){ref-type="fig"}) with additional staining of giant cells and partial staining of endothelial cells within the tumour. In the canine and feline kidney (positive controls), tubules and collecting ducts were stained. Negative controls were negative.

EPO-R IHC resulted in a cytoplasmic staining pattern (total scores ranged from 2 to 9 in both species); a clear membrane staining was not observed ([Figs. 1c, d](#F1){ref-type="fig"}). No differences were found when comparing the C-20 and the M-20 antibodies. All negative controls were negative.

The immunostaining pattern for PDGF-BB was considerably heterogeneous in the osteosarcomas of cats and dogs and total scores ranged from 0 to 9. The staining pattern in canine and feline tumour cells was cytoplasmic ([Fig. 1e](#F1){ref-type="fig"}). In feline osteosarcomas a perivascular distribution of positive cells was partly observed ([Fig. 1f](#F1){ref-type="fig"}). In addition to the tumour cells, giant cells and osteoblasts were positive for PDGF-BB immunostaining in both species. In the positive controls (feline and canine cerebellum), neurons were stained as expected and negative controls were unstained. IHC results are summarised in [Table 1](#T1){ref-type="table"}.

RNA expression analysis {#S12}
-----------------------

*PDGF-B* mRNA was expressed in all feline (*n* = 5) and canine (*n* = 13) samples as well as in the kidney and the bone marrow (positive controls). In contrast, *EPO* mRNA was detected in 38% of the canine tumour samples and 40% of the feline osteosarcoma samples. Four canine samples had a near-threshold level of expression, but were graded as negative.

RT-qPCR showed that the average amount of *EPO-R* mRNA in feline osteosarcomas was higher than that of dogs. The average *Cq* value (±SD) for canine *EPO-R* mRNA (31.8 ± 1.4) was higher than that of the feline *EPO-R* mRNA (26.9 ± 0.5; *P* ≤ 0.001; 94-fold change) ([Fig. 2](#F2){ref-type="fig"}). The tissue samples used as positive controls, kidney and bone marrow, also showed this different expression level of *EPO-R* mRNA between the two species. *Cq* values of canine *EPO-R* mRNA in kidney were 27.4 ± 0.5 compared to 24.8 ± 0.8 in feline kidney (*P* ≤ 0.001; 6.7-fold change). Canine bone marrow samples showed an average *Cq* of 31.2 ± 0.1, whereas feline samples showed an average *Cq* of 25.9 ± 1.6 (39-fold change).

Statistical analysis of bone marrow was not undertaken because of an observed RT-qPCR inhibition in 2/4 canine samples. For each species, the *Cq* values of tumour tissues were significantly lower compared to those in kidney and bone marrow (*P* ≤ 0.05). The expression patterns of primary cell cultures isolated from some of the original osteosarcomas correlated well with those of the original tumour tissue ([Fig. 2](#F2){ref-type="fig"}).

In vitro EPO-R functionality assay {#S13}
----------------------------------

The effects of EPO in vitro are summarised in [Figs. 3](#F3){ref-type="fig"}, [4](#F4){ref-type="fig"}. In the absence of FCS, the feline osteosarcoma cell lines and the canine cell line COS_1189 showed a significant dose-dependent increase in absorbance 2 h and 4 h after alamarBlue addition (FOS_1077: 2 h, *P* = 0.03 and 4 h, *P* = 0.05; FOS_1140: 2 h, *P* \< 0.01 and 4 h, *P* = 0.01; COS_1189: 2 h, *P* \< 0.01 and 4 h, *P* = 0.05) ([Figs. 3](#F3){ref-type="fig"}, [4](#F4){ref-type="fig"}). However, the explained variance was low ranging from 7% to 22%. In COS_1186w cells, the absorbance decreased significantly after 4 h (*P* \< 0.01) but not after 2 h (*P* = 0.52). In FCS supplemented medium, the D-17 cell line showed increased proliferation after 2 h, but not after 4 h. EPO treatment had no effect on all other cell lines.

The relative number of Ki67 positive cells was used as an alternative way to determine the potential growth enhancing effects of EPO on osteosarcoma cells using EPO concentrations of 0.001 U/mL, 1 U/mL and 10 U/mL ([Fig. 5](#F5){ref-type="fig"}). In the presence of FCS, two canine cell lines showed a significant increase of Ki67 positive cells (COS_1186w: *P* = 0.02; COS_1189: *P* = 0.02). Without stimulation by FCS, the numbers of cells for COS_1186w and COS_1189 were insufficient to determine a Ki67 index. All other set ups showed no impact of EPO treatment.

Discussion {#S14}
==========

The potential effect of EPO on tumours has been a longstanding debate. There are two primary mechanisms by which tumour growth could be affected: either via the direct action of EPO on tumour cells expressing a functional EPO-R or indirectly by induction of angiogenesis. Due to the low binding efficiency of EPO to its receptor, these effects should be greatly influenced by the amount of EPO present in the target tissue ([@R62]). Although it is generally assumed that the kidney is the only source of EPO ([@R31]), several other organs ([@R23]; [@R15]; [@R63]) and tumours ([@R53]; [@R5]; [@R43]; [@R17]) also secrete EPO. Serum EPO concentrations are very similar in dogs and cats ([@R9]).

In the current study, EPO, EPO-R and PDGF-BB were detected by IHC in canine and feline osteosarcomas. The EPO and EPO-R immunostaining pattern was comparable between both species. The PDGF-BB results are in accordance with previous reports for dogs ([@R39]). The distribution of PDGF-BB in the cat was partly perivascular in contrast to what was observed in canine tumours. Therefore, a paracrine or autocrine role for these factors is possible in canine and feline osteosarcomas.

The antibodies against EPO-R used in our study (M-20 and C-20) were not generated against the canine or feline EPO-R protein. Sequence similarities, positive controls, peptide blocking experiments, and their prior use on canine tissue by other groups ([@R49]) convinced us of their suitability. It is noteworthy that the specificity of these commercial antibodies has been questioned ([@R7]; [@R29]; [@R19]). Western blotting indicated that only M-20 detects the correct band at 59 kD ([@R18]) while C-20 detects three unspecific bands ([@R19]), rendering them not suitable for IHC ([@R18]). A novel EPO-R-specific antibody, A82, has been developed ([@R54]) but is currently not commercially available.

RT-PCR was used to support the IHC results. *EPO-R* and *PDGF-B* mRNA was present in all feline and canine samples supporting the protein data. Although *EPO* mRNA was only present in less than half of the feline and canine tumour samples, this difference could be explained by the presence of EPO originating from the serum. This finding supports the hypothesis that some of the sampled tumours are capable of autocrine stimulation as shown in other tumour types ([@R25]).

Since [@R20] claimed that *EPO-R* mRNA concentration in tumours is too low to allow the receptor to be expressed on the cell surface, quantitative RT-PCR was used to determine *EPO-R* mRNA levels in canine and feline osteosarcomas. Interestingly, there was a significant difference in *EPO-R* mRNA expression between cat and dog samples. Generally higher amounts of *EPO-R* mRNA were detected in all samples (osteosarcomas, osteosarcoma-derived cells, kidney, and bone marrow) from cats compared with dogs. The primary feline and canine cell cultures maintained *EPO-R* mRNA expression and notably the expression level increased in three of four cell lines. These results confirm that osteosarcoma cells express EPO-R.

Consistent with results from previous studies ([@R54]; [@R19], [@R20]) the amount of *EPO-R* mRNA was lower in the tumour than in the reference tissues. To explain the lack of correlation between IHC results and RT-qPCR data, we should consider that proteins are synthesised much faster and have a longer half-life than mRNAs. Therefore, the correlation between mRNA and protein level is generally poor ([@R2]; [@R8]; [@R56]).

Many tumours, in particular osteosarcomas, have a high level of intratumoural heterogeneity ([@R57]). Therefore, using a small amount of homogenised tumour in PCR or Western blot might not reflect the whole neoplasm ([@R24]; [@R45]; [@R64]), as structures other than tumour cells (blood vessels, stroma, immune cells) will also contribute to the quantitative results.

There is evidence that the expression of *EPO-R* mRNA alone is not sufficient to determine its effect on cells ([@R54]). Therefore, we used an alamarBlue assay and Ki67 immunohistochemistry to test the functional effect of EPO and functionality of EPO-R in an in vitro system. No general proliferation-enhancing effect of EPO on canine or feline osteosarcoma cells was observed. Minimal effects were seen in groups grown in medium without FCS supplementation in the alamarBlue test or in medium with FCS in the Ki67 assay, indicating influences of some undefined growth factors in serum. The anti-apoptotic properties of EPO, leading to longer cell survival in the absence of FCS, may result in higher turn-over measured in the alamarBlue assay, an effect possibly covered by the proliferation-enhancing effects of FCS. The Ki67 assay detected dividing cells, but not prolonged cell survival. Altogether, these results are in accordance with those of [@R50], who reported that EPO did not stimulate the growth of human prostate cells, but protected them from apoptosis.

Conclusions {#S15}
===========

EPO, EPO-R and PDGF-BB were expressed in cat and dog osteosarcomas, but no significant differences between the two species were observed, except for *EPO-R* mRNA expression. These results may suggest potential species-specific growth promoting or inhibiting effects of EPO on tumour cells.
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![Immunohistochemical staining of canine and feline osteosarcomas. (a) Canine osteosarcoma, erythropoietin (EPO); (b) feline osteosarcoma, EPO; tumour cells and stromal cells showed cytoplasmic and nuclear staining. (c) Canine osteosarcoma, erythropoietin receptor (EPO-R); (d) feline osteosarcoma, EPO-R; EPO-R was expressed in tumour cells and giant cells. (e) Canine osteosarcoma, platelet-derived growth factor BB (PDGF-BB); (f) feline osteosarcoma, PDGF-BB; osteosarcoma cells showed a cytoplasmic granular staining pattern. In some samples a perivascular distribution was observed. Scale bar = 100 μm.](emss-64694-f0001){#F1}

![Erythropoietin receptor (*EPO-R*) mRNA expression changes relative to the reference genes *OAZ1* and *C26H12orf43/CD3H12orf43* in canine and feline osteosarcomas and reference tissues as well as in osteosarcoma cell cultures, showing a significant difference between tumours and corresponding tissues, and between canine and feline osteosarcomas. Boxes depict 25%--75% interval, whiskers the 5%--95% interval. Highest and lowest values are indicated by x. Where boxplots were inappropriate, individual values are marked by circles (cat) or rectangles (dog). Tumours and corresponding cell lines are marked by the same shades of grey, and canine bone marrow samples showing inhibition are marked by light grey edging. Significant differences are marked by an asterisk.](emss-64694-f0002){#F2}

![Regression plots of canine cultured cells in the presence of erythropoietin (EPO) (0, 0.1, 0.01, 0.001, 0.0001 and 1 U/well) with or without foetal calf serum (FCS). Regression plots for the 2 h interval are depicted in black and individual values are marked as x. The 4 h interval is depicted in grey showing the individual values as ○. D-17 and COS_1186w cells showed a marked decrease in absorbance in the absence of FCS, but an increase in absorbance after 4 h for D-17 and after 2 h and nearing significance after 4 h in COS_1186w cells when FCS was added. COS_1189 cells showed an increase in absorbance after 4 h (without FCS) and 2 h and 4 h in the presence of FCS.](emss-64694-f0003){#F3}

![Regression plots of feline cultured cells in the presence of erythropoietin (EPO) (0, 0.1, 0.01, 0.001, 0.0001 and 1 U/well) with or without foetal calf serum (FCS). Regression plots for the 2 h interval are depicted in black and individual values are marked as x. The 4 h interval is depicted in grey showing the individual values as ○. FOS_1077 and FCS_1140 cells showed a significant increase in their absorbance in the presence of FCS, but not without FCS.](emss-64694-f0004){#F4}

![Percentage of Ki67 positive stained feline (FOS_1077, FOS_1140) and canine (COS_1186w, COS_1189, D-17) osteosarcoma cell lines after treatment with various concentrations of erythropoietin (EPO) with or without foetal calf serum (FCS). NGC, negative control samples, without FCS or EPO. Circles mark the individual values, bars depict the mean of the treatment group.](emss-64694-f0005){#F5}

###### 

Distribution of immunohistological scores in canine and feline osteosarcomas.

  --------------------------------------------------------------------
  Total IHC score   EPO\         EPO-R\       PDGF-BB\             
                    (*n* = 18)   (*n* = 18)   (*n* = 18)           
  ----------------- ------------ ------------ ------------ --- --- ---
  0                 0            0            0            0   0   1

  1                 0            0            0            0   2   0

  2                 0            1            1            1   5   1

  3                 2            0            4            0   3   1

  4                 1            2            1            1   0   0

  6                 7            0            5            1   3   0

  9                 3            2            2            2   0   2
  --------------------------------------------------------------------

EPO, erythropoietin; EPO-R, erythropoietin receptor; PDGF-BB, platelet-derived growth factor BB.
